| 001 | 904375 | ||
| 005 | 20230123101846.0 | ||
| 024 | 7 | _ | |a 10.1007/s00259-020-05118-w |2 doi |
| 024 | 7 | _ | |a 0340-6997 |2 ISSN |
| 024 | 7 | _ | |a 1432-105X |2 ISSN |
| 024 | 7 | _ | |a 1619-7070 |2 ISSN |
| 024 | 7 | _ | |a 1619-7089 |2 ISSN |
| 024 | 7 | _ | |a 2128/32252 |2 Handle |
| 024 | 7 | _ | |a 33547556 |2 pmid |
| 024 | 7 | _ | |a WOS:000615202400001 |2 WOS |
| 037 | _ | _ | |a FZJ-2021-05945 |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Wolters, E. E. |0 P:(DE-HGF)0 |b 0 |e Corresponding author |
| 245 | _ | _ | |a Clinical validity of increased cortical uptake of [18F]flortaucipir on PET as a biomarker for Alzheimer’s disease in the context of a structured 5-phase biomarker development framework |
| 260 | _ | _ | |a Heidelberg [u.a.] |c 2021 |b Springer-Verl. |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1667372612_31190 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a Purpose: In 2017, the Geneva Alzheimer's disease (AD) Biomarker Roadmap initiative adapted the framework of the systematic validation of oncological diagnostic biomarkers to AD biomarkers, with the aim to accelerate their development and implementation in clinical practice. With this work, we assess the maturity of [18F]flortaucipir PET and define its research priorities.Methods: The level of maturity of [18F]flortaucipir was assessed based on the AD Biomarker Roadmap. The framework assesses analytical validity (phases 1-2), clinical validity (phases 3-4), and clinical utility (phase 5).Results: The main aims of phases 1 (rationale for use) and 2 (discriminative ability) have been achieved. [18F]Flortaucipir binds with high affinity to paired helical filaments of tau and has favorable kinetic properties and excellent discriminative accuracy for AD. The majority of secondary aims of phase 2 were fully achieved. Multiple studies showed high correlations between ante-mortem [18F]flortaucipir PET and post-mortem tau (as assessed by histopathology), and also the effects of covariates on tracer binding are well studied. The aims of phase 3 (early detection ability) were only partially or preliminarily achieved, and the aims of phases 4 and 5 were not achieved.Conclusion: Current literature provides partial evidence for clinical utility of [18F]flortaucipir PET. The aims for phases 1 and 2 were mostly achieved. Phase 3 studies are currently ongoing. Future studies including representative MCI populations and a focus on healthcare outcomes are required to establish full maturity of phases 4 and 5.Keywords: Alzheimer’s disease; Biomarker-based diagnosis; PET; Strategic roadmap; [18F]flortaucipir. |
| 536 | _ | _ | |a 5253 - Neuroimaging (POF4-525) |0 G:(DE-HGF)POF4-5253 |c POF4-525 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, Journals: juser.fz-juelich.de |
| 700 | 1 | _ | |a Dodich, A. |0 P:(DE-HGF)0 |b 1 |
| 700 | 1 | _ | |a Boccardi, M. |0 P:(DE-HGF)0 |b 2 |
| 700 | 1 | _ | |a Corre, J. |0 P:(DE-HGF)0 |b 3 |
| 700 | 1 | _ | |a Drzezga, Alexander |0 P:(DE-Juel1)177611 |b 4 |
| 700 | 1 | _ | |a Hansson, O. |0 P:(DE-HGF)0 |b 5 |
| 700 | 1 | _ | |a Nordberg, A. |0 P:(DE-HGF)0 |b 6 |
| 700 | 1 | _ | |a Frisoni, G. B. |0 P:(DE-HGF)0 |b 7 |
| 700 | 1 | _ | |a Garibotto, V. |0 P:(DE-HGF)0 |b 8 |
| 700 | 1 | _ | |a Ossenkoppele, R. |0 P:(DE-HGF)0 |b 9 |
| 773 | _ | _ | |a 10.1007/s00259-020-05118-w |g Vol. 48, no. 7, p. 2097 - 2109 |0 PERI:(DE-600)2098375-X |n 7 |p 2097 - 2109 |t European journal of nuclear medicine and molecular imaging |v 48 |y 2021 |x 0340-6997 |
| 856 | 4 | _ | |y OpenAccess |z StatID:(DE-HGF)0510 |u https://juser.fz-juelich.de/record/904375/files/FZJ-2021-05945_Clinical%20validity%20of%20increased%20cortical_Wolters.pdf |
| 856 | 4 | _ | |y Restricted |z StatID:(DE-HGF)0599 |u https://juser.fz-juelich.de/record/904375/files/Wolters2021_Article_ClinicalValidityOfIncreasedCor.pdf |
| 909 | C | O | |o oai:juser.fz-juelich.de:904375 |p openaire |p open_access |p VDB |p driver |p dnbdelivery |
| 910 | 1 | _ | |a Department of Radiology & Nuclear Medicine, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, location VUmc, PO Box 7057, 1007 MB, Amsterdam, The Netherlands. e.e.wolters-2@umcutrecht.nl |0 I:(DE-HGF)0 |b 0 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands. e.e.wolters-2@umcutrecht.nl |0 I:(DE-HGF)0 |b 0 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a NIMTlab - Neuroimaging and Innovative Molecular Tracers Laboratory, University of Geneva, Geneva, Switzerland |0 I:(DE-HGF)0 |b 1 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Centre for Mind/Brain Sciences-CIMeC, University of Trento, Rovereto, Italy |0 I:(DE-HGF)0 |b 1 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Late Translational Dementia Studies Group, German Center for Neurodegenerative Diseases (DZNE), Rostock-Greifswald site, Rostock, Germany |0 I:(DE-HGF)0 |b 2 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a NIMTlab - Neuroimaging and Innovative Molecular Tracers Laboratory, University of Geneva, Geneva, Switzerland |0 I:(DE-HGF)0 |b 3 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a CURIC, Centre Universitaire Romand d'Implants Cochléaires, Department of Clinical Neurosciences, University of Geneva, Geneva, Switzerland |0 I:(DE-HGF)0 |b 3 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 4 |6 P:(DE-Juel1)177611 |
| 910 | 1 | _ | |a Faculty of Medicine, University of Cologne, Cologne, Germany |0 I:(DE-HGF)0 |b 4 |6 P:(DE-Juel1)177611 |
| 910 | 1 | _ | |a German Center for Neurodegenerative Diseases (DZNE), Bonn-Cologne, Germany |0 I:(DE-HGF)0 |b 4 |6 P:(DE-Juel1)177611 |
| 910 | 1 | _ | |a Memory Clinic, Skåne University Hospital, Malmö, Sweden |0 I:(DE-HGF)0 |b 5 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University, Lund, Sweden |0 I:(DE-HGF)0 |b 5 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Division of Clinical Geriatrics, Center for Alzheimer Research, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden |0 I:(DE-HGF)0 |b 6 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a LANVIE - Laboratory of Neuroimaging of Aging, University of Geneva, Geneva, Switzerland |0 I:(DE-HGF)0 |b 7 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Memory Clinic, University Hospital, Geneva, Switzerland |0 I:(DE-HGF)0 |b 7 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a NIMTlab - Neuroimaging and Innovative Molecular Tracers Laboratory, University of Geneva, Geneva, Switzerland |0 I:(DE-HGF)0 |b 8 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands |0 I:(DE-HGF)0 |b 9 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University, Lund, Sweden |0 I:(DE-HGF)0 |b 9 |6 P:(DE-HGF)0 |
| 913 | 1 | _ | |a DE-HGF |b Key Technologies |l Natural, Artificial and Cognitive Information Processing |1 G:(DE-HGF)POF4-520 |0 G:(DE-HGF)POF4-525 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-500 |4 G:(DE-HGF)POF |v Decoding Brain Organization and Dysfunction |9 G:(DE-HGF)POF4-5253 |x 0 |
| 914 | 1 | _ | |y 2022 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2021-02-02 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2021-02-02 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2021-02-02 |
| 915 | _ | _ | |a Creative Commons Attribution CC BY 4.0 |0 LIC:(DE-HGF)CCBY4 |2 HGFVOC |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2021-02-02 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b EUR J NUCL MED MOL I : 2019 |d 2021-02-02 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2021-02-02 |
| 915 | _ | _ | |a DEAL Springer |0 StatID:(DE-HGF)3002 |2 StatID |d 2021-02-02 |w ger |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2021-02-02 |
| 915 | _ | _ | |a OpenAccess |0 StatID:(DE-HGF)0510 |2 StatID |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2021-02-02 |
| 915 | _ | _ | |a IF >= 5 |0 StatID:(DE-HGF)9905 |2 StatID |b EUR J NUCL MED MOL I : 2019 |d 2021-02-02 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2021-02-02 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2021-02-02 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2021-02-02 |
| 920 | _ | _ | |l yes |
| 920 | 1 | _ | |0 I:(DE-Juel1)INM-2-20090406 |k INM-2 |l Molekulare Organisation des Gehirns |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a UNRESTRICTED |
| 980 | _ | _ | |a I:(DE-Juel1)INM-2-20090406 |
| 980 | 1 | _ | |a FullTexts |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|
guest ::